We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$193M
AUM Growth
-$17.7M
Cap. Flow
+$46.7M
Cap. Flow %
24.24%
Top 10 Hldgs %
52.19%
Holding
80
New
22
Increased
10
Reduced
12
Closed
26

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$23.6M
2
DMK
DMK Pharmaceuticals Corporation Common Stock
DMK
+$9.19M
3
BIIB icon
Biogen
BIIB
+$4.6M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$3.86M
5
ZBH icon
Zimmer Biomet
ZBH
+$3.69M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$6.61M
2
TMO icon
Thermo Fisher Scientific
TMO
+$6.28M
3
HCA icon
HCA Healthcare
HCA
+$5.27M
4
PBYI icon
Puma Biotechnology
PBYI
+$4.91M
5
PHG icon
Philips
PHG
+$4.9M

Sector Composition

Rank Sector Weight
1 Healthcare 59.52%
2 Financials 4.17%
3 Technology 0.91%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITGR icon
26
Integer Holdings
ITGR
$3.38B
$2.62M 1.36%
+51,258
New +$2.35M
ISRG icon
27
PUT
Intuitive Surgical
ISRG
$128B
$2.62M 1.36%
22,500
-60,300
-73% -$6.57M
ELV icon
28
Elevance Health
ELV
$82.1B
$2.55M 1.32%
13,418
-349
-3% -$66.4K
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$37.2B
$2.38M 1.23%
+20,225
New +$1.73M
LMNX
30
DELISTED
Luminex Corp
LMNX
$2.36M 1.22%
115,979
– –
VRTX icon
31
Vertex Pharmaceuticals
VRTX
$122B
$2.26M 1.17%
+14,874
New +$2.24M
SNY icon
32
Sanofi
SNY
$105B
$2.25M 1.16%
45,099
-136,523
-75% -$6.61M
UNH icon
33
UnitedHealth
UNH
$379B
$2.24M 1.16%
11,430
-9,721
-46% -$1.88M
GYRE icon
34
Gyre Therapeutics
GYRE
$683M
$2.13M 1.11%
56,218
+9,128
+19% +$274K
ARNA
35
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.84M 0.95%
72,086
+2,734
+4% +$62.7K
VCRA
36
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$1.76M 0.91%
56,106
– –
EVH icon
37
Evolent Health
EVH
$429M
$1.4M 0.73%
+78,600
New +$1.62M
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$12.7B
$1.21M 0.63%
+26,958
New +$505K
AVDL
39
DELISTED
Avadel Pharmaceuticals
AVDL
$960K 0.5%
91,413
– –
ATNM icon
40
Actinium Pharmaceuticals
ATNM
$26.8M
$915K 0.47%
+53,009
New +$1.16M
FOMX
41
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$773K 0.4%
139,200
– –
DBVT
42
PUT
DBV Technologies
DBVT
$823M
$772K 0.4%
+1,820
New +$780K
XNCR icon
43
Xencor
XNCR
$1.47B
$759K 0.39%
+33,100
New +$735K
ACHC icon
44
PUT
Acadia Healthcare
ACHC
$2.99B
$659K 0.34%
+13,800
New +$673K
PGNX
45
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$652K 0.34%
+88,523
New +$562K
SYRE icon
46
Spyre Therapeutics
SYRE
$8.69B
$639K 0.33%
5,183
– –
CBAY
47
DELISTED
Cymabay Therapeutics
CBAY
$605K 0.31%
+75,000
New +$507K
OTIC
48
DELISTED
Otonomy, Inc.
OTIC
$328K 0.17%
+100,900
New +$1.36M
OTIC
49
PUT
DELISTED
Otonomy, Inc.
OTIC
$328K 0.17%
+100,900
New +$1.36M
PFNX
50
DELISTED
Pfenex Inc.
PFNX
$259K 0.13%
85,867
– –
1
2
3 4

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
CA
Cortland Associates St Louis, Missouri $697M AUM 4.23% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return

Sio Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sio Capital Management held 80 positions worth $193M, down 8.4% from $210M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Sio Capital Management deployed $46.7M of net new capital in Q3 2017, opening 22 new positions and adding to 10 existing holdings. Its largest new stake was Sio Gene Therapies Inc. Common Stock: 139,862 shares worth $7.7M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 51% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Sanofi, an estimated $6.61M trimmed.

  • Sio Capital Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 139,862 shares worth $7.7M.
  • Sio Capital Management added most to DMK Pharmaceuticals Corporation Common Stock in Q3 2017, an estimated $9.19M increase.
  • Sio Capital Management's biggest Q3 2017 reduction was Sanofi, cutting an estimated $6.61M.
  • Sio Capital Management fully exited Thermo Fisher Scientific in Q3 2017, selling an estimated $6.28M.
  • Sio Capital Management's ten largest holdings make up 52% of its $193M portfolio in Q3 2017.
  • Sio Capital Management opened 22 new positions and closed 26 in Q3 2017.
  • Sio Capital Management's portfolio value fell 8.4% quarter-over-quarter to $193M.

Based on Sio Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.